31.90
-1.30 (-3.92%)
| Previous Close | 33.20 |
| Open | 33.07 |
| Volume | 1,568,268 |
| Avg. Volume (3M) | 1,641,781 |
| Market Cap | 3,044,600,064 |
| Price / Sales | 38.52 |
| Price / Book | 10.20 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Operating Margin (TTM) | -130,369.45% |
| Diluted EPS (TTM) | -3.35 |
| Total Debt/Equity (MRQ) | 3.82% |
| Current Ratio (MRQ) | 19.49 |
| Operating Cash Flow (TTM) | -279.75 M |
| Levered Free Cash Flow (TTM) | -171.41 M |
| Return on Assets (TTM) | -32.62% |
| Return on Equity (TTM) | -51.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Viridian Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 1.63 |
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 114.61% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Vr Adviser, Llc | 30 Sep 2025 | 3,882,709 |
| Fairmount Funds Management Llc | 30 Sep 2025 | 3,459,913 |
| Maverick Capital Ltd | 30 Sep 2025 | 2,212,701 |
| Eversept Partners, Lp | 30 Sep 2025 | 1,924,306 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (UBS, 56.74%) | Buy |
| Median | 43.50 (36.36%) | |
| Low | 29.00 (Wells Fargo, -9.09%) | Hold |
| Average | 42.17 (32.19%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 31.34 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 04 Feb 2026 | 42.00 (31.66%) | Buy | 33.53 |
| 23 Dec 2025 | 42.00 (31.66%) | Buy | 32.11 | |
| Wells Fargo | 03 Feb 2026 | 29.00 (-9.09%) | Hold | 33.53 |
| Truist Securities | 08 Jan 2026 | 40.00 (25.39%) | Buy | 30.33 |
| 24 Nov 2025 | 41.00 (28.53%) | Buy | 32.03 | |
| UBS | 07 Jan 2026 | 50.00 (56.74%) | Buy | 30.57 |
| Wedbush | 10 Dec 2025 | 47.00 (47.34%) | Buy | 32.60 |
| RBC Capital | 06 Nov 2025 | 45.00 (41.07%) | Buy | 27.50 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Jan 2026 | Announcement | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 06 Jan 2026 | Announcement | Viridian Therapeutics Prepares for Transformational 2026 |
| 22 Dec 2025 | Announcement | Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease |
| 05 Dec 2025 | Announcement | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 07 Nov 2025 | Announcement | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 05 Nov 2025 | Announcement | Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |